181 related articles for article (PubMed ID: 24516540)
1. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
Caleca L; Putignano AL; Colombo M; Congregati C; Sarkar M; Magliery TJ; Ripamonti CB; Foglia C; Peissel B; Zaffaroni D; Manoukian S; Tondini C; Barile M; Pensotti V; Bernard L; Papi L; Radice P
PLoS One; 2014; 9(2):e86924. PubMed ID: 24516540
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg).
Willems P; Magri V; Cretnik M; Fasano M; Jakubowska A; Levanat S; Lubinski J; Marras E; Musani V; Thierens H; Vandersickel V; Perletti G; Vral A
Int J Oncol; 2009 Apr; 34(4):1005-15. PubMed ID: 19287957
[TBL] [Abstract][Full Text] [Related]
3. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
[TBL] [Abstract][Full Text] [Related]
4. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
Apostolou P; Pertesi M; Aleporou-Marinou V; Dimitrakakis C; Papadimitriou C; Razis E; Christodoulou C; Fountzilas G; Yannoukakos D; Konstantopoulou I; Fostira F
Clin Genet; 2017 Mar; 91(3):482-487. PubMed ID: 27357818
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
6. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.
Baudi F; Quaresima B; Grandinetti C; Cuda G; Faniello C; Tassone P; Barbieri V; Bisegna R; Ricevuto E; Conforti S; Viel A; Marchetti P; Ficorella C; Radice P; Costanzo F; Venuta S
Hum Mutat; 2001 Aug; 18(2):163-4. PubMed ID: 11462242
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
9. The
Aretini P; Presciuttini S; Pastore A; Galli A; Panepinto S; Tancredi M; Ghilli M; Guglielmi C; Sidoti D; Congregati C; Caligo MA
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958491
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
[TBL] [Abstract][Full Text] [Related]
11. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Brzovic PS; Rajagopal P; Hoyt DW; King MC; Klevit RE
Nat Struct Biol; 2001 Oct; 8(10):833-7. PubMed ID: 11573085
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
13. Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Fragoso-Ontiveros V; Velázquez-Aragón JA; Nuñez-Martínez PM; de la Luz Mejía-Aguayo M; Vidal-Millán S; Pedroza-Torres A; Sánchez-Contreras Y; Ramírez-Otero MA; Muñiz-Mendoza R; Domínguez-Ortíz J; Wegman-Ostrosky T; Bargalló-Rocha JE; Gallardo-Rincón D; Reynoso-Noveron N; Arriaga-Canon C; Meneses-García A; Herrera-Montalvo LA; Alvarez-Gomez RM
PLoS One; 2019; 14(9):e0222709. PubMed ID: 31545835
[TBL] [Abstract][Full Text] [Related]
14. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Dizin E; Irminger-Finger I
Int J Biochem Cell Biol; 2010 May; 42(5):693-700. PubMed ID: 20060929
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Muller D; Bonaiti-Pellié C; Abecassis J; Stoppa-Lyonnet D; Fricker JP
Fam Cancer; 2004; 3(1):15-20. PubMed ID: 15131401
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
17. Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
Tuazon AMA; Lott P; Bohórquez M; Benavides J; Ramirez C; Criollo A; Estrada-Florez A; Mateus G; Velez A; Carmona J; Olaya J; Garcia E; Polanco-Echeverry G; Stultz J; Alvarez C; Tapia T; Ashton-Prolla P; ; Vega A; Lazaro C; Tornero E; Martinez-Bouzas C; Infante M; De La Hoya M; Diez O; Browning BL; ; Rannala B; Teixeira MR; Carvallo P; Echeverry M; Carvajal-Carmona LG
Breast Cancer Res; 2020 Oct; 22(1):108. PubMed ID: 33087180
[TBL] [Abstract][Full Text] [Related]
18. Identification of a founder BRCA1 mutation in the Moroccan population.
Quiles F; Teulé À; Martinussen Tandstad N; Feliubadaló L; Tornero E; Del Valle J; Menéndez M; Salinas M; Wethe Rognlien V; Velasco A; Izquierdo A; Capellá G; Brunet J; Lázaro C
Clin Genet; 2016 Oct; 90(4):361-5. PubMed ID: 26864382
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
Meng H; Yao L; Yuan H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(11):3044-3052. PubMed ID: 31957001
[TBL] [Abstract][Full Text] [Related]
20. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
